LBA 05 - NRG-HN009 Randomized Phase II/III Trial of RT + Cisplatin Q3 Weeks vs RT + Cisplatin Weekly for Patients with Locoregionally Advanced SCCHN: p16-Negative Phase II Toxicity Results

02:55pm - 03:05pm ET

Presenter(s)

Paul Harari, MD, FASTRO - University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin